ArticleCancer immunology, immunotherapy : CII2025

Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs).

Adrien Costantini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.